By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Janssen Pharmaceutical Inc.  

1125 Trenton-Harbourton Road

Titusville  New Jersey  08560  U.S.A.
Phone: 609-730-2000 Fax: n/a


SEARCH JOBS


Industry
Pharmaceutical






Company News
Janssen Pharmaceutical Wins Prestigious International Prix Galien Award For MDR-TB Treatment 12/9/2016 9:31:11 AM
Janssen Pharmaceutical Release: New Analysis Shows People With Cancer Who Received XARELTO (Rivaroxaban) For Blood Clots Had Fewer ER Visits And Lower Healthcare Costs Than Those Given Standard Treatment 12/6/2016 8:49:13 AM
Achillion (ACHN) Announces Initiation Of Patient Dosing By Janssen Pharmaceutical In A Global, Short Treatment-Duration Phase 2b Study Of JNJ-4178 In Chronic HCV 11/30/2016 7:58:23 AM
Janssen Pharmaceutical Release: Phase 3b Study Shows Significantly Less Bleeding With XARELTO (Rivaroxaban) Compared To Warfarin In People With Non-Valvular Atrial Fibrillation Following Percutaneous Coronary Intervention With Stenting 11/14/2016 10:26:00 AM
Janssen Pharmaceutical Release: Two New Real-World Studies Confirm Positive Efficacy And Safety Profile Of XARELTO (Rivaroxaban) In Treating And Preventing Blood Clots 10/24/2016 7:21:32 AM
Janssen Pharmaceutical Release: U.S. FDA Approves INVOKAMET XR (Canagliflozin / Metformin Hydrochloride Extended-Release) For The Treatment Of Adults With Type 2 Diabetes 9/21/2016 8:18:00 AM
Janssen Pharmaceutical Announces 25 Presentations At Upcoming European Society of Cardiology Congress 2016, Including New Clinical And Real-World Research On XARELTO And Latest Findings From REVISIT-US 8/22/2016 8:44:28 AM
Achillion (ACHN) Announces Upcoming Presentation Of Interim Phase IIa Results From The Janssen Pharmaceutical Sponsored Trial Of Odalasvir, AL-335 And Simeprevir At The European Association For The Study Of The Liver (EASL) Special Conference 8/11/2016 10:54:21 AM
Janssen Pharmaceutical Presents New Data Showing Invokana (Canagliflozin) Is Associated With Greater Blood Glucose Control And Treatment Adherence Compared To Dpp-4 Inhibitors 6/13/2016 11:17:17 AM
ASCO2016: Janssen Pharmaceutical Release: Daratumumab (DARZALEX) Combination Therapy Significantly Extended Progression-Free Survival In Previously Treated Patients With Multiple Myeloma 6/6/2016 1:14:01 PM
1234567
//-->